CLINICAL-APPLICATION OF RECOMBINANT ERYTHROPOIETIN IN THE PERIOPERATIVE PERIOD

被引：17

作者：

GOODNOUGH, LT

机构：

[1] WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110

[2] WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110

[3] BARNES HOSP,DEPT TRANSFUS SERV,ST LOUIS,MO

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1994年 / 8卷 / 05期

关键词：

D O I：

10.1016/S0889-8588(18)30144-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recombinant human erythropoietin (EPO) therapy as an alternative to allogenic blood transfusion has been studied extensively in the perisurgical period. The potential benefits of EPO in this setting are twofold; EPO enhances autologous blood collection in advance of elective surgery and stimulates erythropoiesis perioperatively. Clinical evidence of the role of EPO therapy in these settings to minimize allogenic blood exposure is presented.

引用

页码：1011 / &

共 56 条

[1]

BESARAB A, 1992, J AM SOC NEPHROL, V2, P1405

[2] THE COST-EFFECTIVENESS OF PREOPERATIVE AUTOLOGOUS BLOOD DONATION FOR TOTAL HIP AND KNEE REPLACEMENT [J].